Lilly pays up to $7B for Kelonia in bid to reinvent cancer cell therapy
What's the deal? Eli LillyDealroom has a profile for this one. Try Dealroom → has agreed to acquire Kelonia Therapeutics, a Boston-based clinical-stage biotech, for up to $7B. Kelonia shareholders will receive $3.25B upfront in cash, with up to $3.75B in additional payments tied to clinical, regulatory, and commercial milestones. The deal is expected to close in the second half of 2026.
Kelonia's lead asset, KLN-1010, is a next-generation cancer treatment for multiple myeloma — a blood cancer — that works by instructing the patient's own immune cells, inside the body, to attack the tumour. Unlike conventional CAR-T therapies, which require harvesting a patient's cells, reprogramming them in a laboratory, and reinfusing them after chemotherapy, KLN-1010 does this entirely within the body in a single intravenous dose. Early clinical data presented at the 2025 American Society of Hematology Annual Meeting showed promising tolerability and early signs of efficacy.
Why now? Lilly has been on an aggressive acquisition spree, funded by strong revenues from its weight-loss drug portfolio. The Kelonia deal follows its acquisition of Centessa Pharmaceuticals for approximately $6.3B in March 2026, Orna Therapeutics for up to $2.4B in February, and Ventyx Biosciences for approximately $1.2B in January. Cancer drugs already account for $9.4B of Lilly's $65.2B in total revenue, and it is actively building its oncology pipeline to reduce dependence on its obesity and diabetes franchise.
Kelonia's approach addresses a genuine bottleneck in cancer treatment. Conventional CAR-T therapies — though powerful — are only accessible to a fraction of eligible patients due to their manufacturing complexity, cost, and the requirement for pre-treatment chemotherapy. An off-the-shelf, in-body version could dramatically expand access.
What could go wrong? KLN-1010 is only in Phase 1 — very early stage. The gap between promising early data and a commercially approved product is enormous, and the history of oncology drug development is littered with therapies that showed early promise but failed in larger trials.
With $3.75B of the $7B price tag contingent on milestones, Lilly has structured the deal to limit downside, but the $3.25B upfront is still a substantial bet on unproven technology.
The signal: The deal is part of a broader transformation underway in cancer treatment — moving from drugs that manage tumours to therapies that harness the body's own immune system to eliminate them. Lilly is effectively betting that in vivo cell therapies will be the next wave of oncology innovation, and that owning the platform early — before large-scale trials validate it — is worth the premium.
Kelonia's acquisition also continues Lilly's pattern of buying Boston-area biotechs, where it has been expanding its genetic medicines presence since opening a Seaport Innovation Center in 2024. With four major acquisitions in under four months, the company is making one of the most aggressive biotech M&A pushes in the industry.
Sources:
Eli Lilly
Bloomberg
Wall Street Journal
CNBC
STAT News
Boston Globe
Boston Business Journal
Pharmaceutical Executive
Image generated by AI
J.V.
